The Era of PARP inhibitors in Ovarian Cancer: “Class Action” or not? A Systematic Review and Meta-Analysis

Among epithelial ovarian cancer (EOC) patients, women with genetic predisposition show an early onset of disease. Rare high penetrant mutations in BRCA1 and BRCA2 genes greatly increase lifetime risk and account for the majority of hereditary cases, 10% –15% of all cases. These women have a 40-60% lifetime risk of EOC (44% in BRCA1 families and 27% in BRCA2 families, respectively) (Mavaddat et al., 2012; Xu et al., 2017).

Source: Critical Reviews in Oncology Hematology - September 3, 2018 Category: Cancer & Oncology Authors: Nicoletta Staropoli, Domenico Ciliberto, Teresa Del Giudice, Eleonora Iuliano, Maria Cuc è, Francesco Grillone, Angela Salvino, Vito Aldo Barbieri, Antonio Russo, Pierfrancesco Tassone, Pierosandro Tagliaferri Source Type: research